公开(公告)号：US20220105207A1

公开(公告)日：2022-04-07

申请号：US17552984

申请日：2021-12-16

Applicant: Wisconsin Alumni Research Foundation

Inventor： Jamey Weichert ,  Reinier Hernandez ,  Ray Zhang ,  Anatoly Pinchuk

IPC: A61K51/04 ,  A61K9/00 ,  A61B5/055 ,  C07B59/00 ,  A61K49/00 ,  C07F9/6524 ,  A61K49/10 ,  A61K49/08

Abstract: Dual-modality contrast agents are disclosed herein, having the general formula: R1 includes a chelating moiety that is chelated to a Mn2+ isotope. The disclosed contrast agents differentially target a wide range of malignant tumor tissues, and can be simultaneously used as contrast agents for both magnetic resonance imaging (MRI) and positron emission topography (PET) imaging. Accordingly, the disclosed contrast agent can be used in diagnosing and monitoring solid tumor cancers.

公开(公告)号：US11186598B2

公开(公告)日：2021-11-30

申请号：US16891181

申请日：2020-06-03

Applicant: Wisconsin Alumni Research Foundation

Inventor： Jamey Weichert ,  Anatoly Pinchuk ,  Reinier Hernandez

IPC: A61K51/00 ,  A61M36/14 ,  C07F9/6524 ,  C07B59/00 ,  G01N33/574 ,  A61K51/04 ,  A61N5/10 ,  G01N33/60

Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula: R1 includes a chelating agent that is chelated to a metal atom, wherein the metal atom is a positron or single photon emitting metal isotope with a half life of greater than or equal to 4 hours, or an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2.

公开(公告)号：US20250152759A1

公开(公告)日：2025-05-15

申请号：US18947271

申请日：2024-11-14

Applicant: Wisconsin Alumni Research Foundation

Inventor： Andrew Baschnagel ,  Randall Kimple ,  Reinier Hernandez ,  Aaron LeBeau

IPC: A61K51/10 ,  C07K16/22 ,  C07K16/28

Abstract: The present application provides constructs comprising a single-domain antibody (sdAb) moiety that specifically recognizes mesenchymal epithelial transition factor receptor (MET). Also provided are methods of making and using these constructs.

公开(公告)号：US20180126012A1

公开(公告)日：2018-05-10

申请号：US15809427

申请日：2017-11-10

Applicant: Wisconsin Alumni Research Foundation

Inventor： Jamey Weichert ,  Paul Sondel ,  Ravi Patel ,  Zachary Morris ,  Peter Carlson ,  Reinier Hernandez ,  Joseph Grudzinski

IPC: A61K51/04 ,  A61P35/00 ,  A61K41/00 ,  A61K51/10 ,  A61K9/00 ,  A61P35/04 ,  A61K38/20 ,  A61K39/395

CPC classification number: A61K51/0485 ,  A61K9/0019 ,  A61K38/2013 ,  A61K39/39541 ,  A61K39/39558 ,  A61K41/0038 ,  A61K51/0408 ,  A61K51/0489 ,  A61K51/0497 ,  A61K51/1045 ,  A61K2039/505 ,  A61N5/00 ,  A61N5/1001 ,  A61N2005/1021 ,  A61P35/00 ,  A61P35/04 ,  A61P37/04 ,  C07K14/52 ,  C07K16/2818 ,  C07K16/3084 ,  C07K2319/35 ,  A61K2300/00

Abstract: The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula: wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.

公开(公告)号：US20190184040A1

公开(公告)日：2019-06-20

申请号：US16222364

申请日：2018-12-17

Applicant: Wisconsin Alumni Research Foundation

Inventor： Jamey Weichert ,  Reinier Hernandez ,  Ray Zhang ,  Anatoly Pinchuk

IPC: A61K51/04 ,  C07B59/00 ,  A61B5/055 ,  A61K9/00

CPC classification number: A61K51/0474 ,  A61B5/055 ,  A61K9/0019 ,  C07B59/002

Abstract: Dual-modality contrast agents are disclosed herein, having the general formula: R1 includes a chelating moiety that is chelated to a Mn2+ isotope. The disclosed contrast agents differentially target a wide range of malignant tumor tissues, and can be simultaneously used as contrast agents for both magnetic resonance imaging (MRI) and positron emission topography (PET) imaging. Accordingly, the disclosed contrast agent can be used in diagnosing and monitoring solid tumor cancers.

公开(公告)号：US20180022768A1

公开(公告)日：2018-01-25

申请号：US15343604

申请日：2016-11-04

Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION

Inventor： Jamey Weichert ,  Anatoly Pinchuk ,  Reinier Hernandez

IPC: C07F9/6524 ,  G01N33/60 ,  A61N5/10 ,  A61K51/04

CPC classification number: C07F9/6524 ,  A61K51/0482 ,  A61K51/0489 ,  A61N5/10 ,  C07B59/004 ,  G01N33/574 ,  G01N33/60

Abstract: Alkylphosphocholine analogs incorporating a chelating moiety that chelates a radioactive metal isotope are disclosed herein. The alkylphophocholine analogs, which can be used to treat or detect solid tumors, have the formula: R1 includes a chelating agent that is chelated to a metal atom, wherein the metal atom is a positron or single photon emitting metal isotope with a half life of greater than or equal to 4 hours, or an alpha, beta or Auger emitting metal isotope with a half life of greater than 6 hours and less than 30 days; a is 0 or 1; n is an integer from 12 to 30; m is 0 or 1; Y is —H, —OH, —COOH, —COOX, —OCOX, or —OX, wherein X is an alkyl or an arylalkyl; R2 is —N+H3, —N+H2Z, —N+HZ2, or —N+Z3, wherein each Z is independently an alkyl or an aroalkyl; and b is 1 or 2.

公开(公告)号：US20240287462A1

公开(公告)日：2024-08-29

申请号：US18624848

申请日：2024-04-02

Applicant: Wisconsin Alumni Research Foundation

Inventor： Peiman HEMATTI ,  John KINK ,  Christian CAPITINI ,  Matthew FORSBERG ,  Nicholas HESS ,  Zachary ROSENKRANS ,  Reinier Hernandez

IPC: C12N5/0775 ,  A61K35/15 ,  A61K35/35 ,  C12N5/0786

CPC classification number: C12N5/0668 ,  A61K35/15 ,  A61K35/35 ,  C12N5/0645 ,  C12N2500/84 ,  C12N2502/1323 ,  C12N2502/1358

Abstract: The disclosure relates to populations of educated macrophages and monocytes generated ex vivo or in vivo, and methods of making and using the same using lipid A aminoalkyl glucosaminide phosphate molecules, such as CRX molecules or extracellular vesicles (EVs) from mesenchymal stromal cells (MSC) stimulated with CRX molecules. Also described are EVs and methods for making and using the same from MSCs exposed to CRX.

公开(公告)号：US20230398242A1

公开(公告)日：2023-12-14

申请号：US18332457

申请日：2023-06-09

Applicant: Wisconsin Alumni Research Foundation

Inventor： Reinier Hernandez ,  Aaron LeBeau ,  Chris Massey ,  Zachary Rosenkrans ,  Joseph Gallant

IPC: A61K51/10

CPC classification number: A61K51/1075

Abstract: This disclosure relates to fibroblast activation immune-Pet for detection of fibrosis activity.

公开(公告)号：US20250082797A1

公开(公告)日：2025-03-13

申请号：US18829184

申请日：2024-09-09

Applicant: Wisconsin Alumni Research Foundation

Inventor： Reinier Hernandez ,  Anatoly Pinchuk ,  Liudmila Lambert Lepesevich ,  Zachary Rosenkrans ,  Anna Thickens ,  Nathan Clemons

IPC: A61K51/12 ,  A61K51/04

Abstract: Methods of radiolabeling of cell surface glycans for in vivo cell tracking and imaging as well as populations of radiolabeled cells and uses thereof are disclosed.

公开(公告)号：US12156921B2

公开(公告)日：2024-12-03

申请号：US18303708

申请日：2023-04-20

Applicant: Wisconsin Alumni Research Foundation

Inventor： Reinier Hernandez ,  Anatoly Pinchuk

IPC: A61K51/04 ,  A61P13/08 ,  A61P35/00

Abstract: Theranostic agents incorporating a chelating moiety that can chelate a radioactive metal isotope and a PSMA-targeting moiety are disclosed herein. The theranostic agents, which can be used to treat and/or detect cancers associated with increased PSMA expression, have the formula: and include complexes, anions or salts thereof. R1 includes a chelating moiety; a is 0 or 1; n is an integer from 12 to 21; and R2 includes a prostate specific membrane antigen (PSMA)-targeting moiety. Optionally, the chelating moiety is chelated to a metal atom, where the metal atom is a positron or single photon emitting metal isotope, or an alpha, beta, or Auger emitting metal isotope.